Thank today and quarter thanks for everyone, us you, Raf. joining first our for Good morning, call.
we release, I'm a execution quarter the of our operational while of as a We As success year. System. you PPI financial enabling result strategy performance. commercial our delivered discipline team's start growth incredibly and on to demonstrating had our customers great strong proud and of press and our continued in Business saw another ongoing focus our the our of strong proven success
let me the So recap first financials.
Our the was $XX.XX in revenue billion. quarter
Our a adjusted expanded per delivered XX%. adjusted QX operating X% operating achieving to our we income margin year-over-year EPS We And performance, to increase strong billion. of quarter was in $X.XX $X.XX adjusted another share.
Our performance to and differentiated us quarter first the up guidance to deliver is us our XXXX. sets in in performance allowing raise
first Turning performance the to underlying we'd market by In our quarter, as out expected. end played conditions market.
revenue our execution performance differentiated to excellent team's deliver expectations. was us of ahead enabled Our that
let provide performance Now low you which the Starting single pharma in QX digits additional improvement We some in was the with a me sequential context. declined and for XXXX. quarter, over biotech.
delivered and pandemic-related worked strong and In government this caused also clinical we academic quick down in as the reminder had that on analytical of year segment. ago, instruments applied. in was X-point growth revenue very a strong and resulted quarter, the headwind And for A by we chain shipments and backlog industrial disruptions. A vaccine the first our customer business. therapy research we runoff supply
safety research low We during microscopy as quarter. business in declined in the the delivered academic our digits our government, channel. result and single strong in as electron growth in a market and well As we
our Industrial in we strong In the this single delivered low in quarter. in business electron segment. Applied, digits declined and the We for microscopy growth
of high declined COVID-XX we by this in end growth impacted QX, in single Healthcare and digits. runoff market was reported Diagnostics in in the Finally, the testing-related The revenue.
highlighted was by growth as quarter, immunodiagnostics the channel. our market diagnostics our as revenue and health transplant During well care businesses core
up end out year. expected start Underlying we as the our to So conditions on played market markets. wrapping
the recall, in XXXX you as pickup our progresses. As assumption for year is a see we'll activity economic that modest
quarter, a view, developments program positive see the couple it of and that support the funding improvements end our markets continued was good including the China. During environment biotech to this by announced in stimulus in
I'll our growth to now turn an update strategy. on
pillars: We excellent engine. a As number consists to our reminder, trusted of Starting the start unparalleled pillar, and year, our commercial products with during quarter. strategy partner innovation. the status first our the a X businesses our had of an high-impact customers with first launching new across innovation, high-impact
highlight instruments first our continued a analytical market Let products number that demonstrate in of me leadership.
spectrometry and Scientific faster system, we more the streamlined resolution, identify and contaminants environmental which mass for time results to enables Inuvion In our Chromatography higher to launched testing. Dionex Thermo chromatography workflows business, Ion efficiently
GX instrument In handheld our business, safety, Thermo the battery rapid Handheld identification also a Analyzer, to enhance production. Thermo of production. used performance we Scientific Metrology Analysis solution Edge TruScan in for Chemical chemical launched the we next-generation launched Raman LInspector In-line And compounds the Scientific and drug
PangenomiX And including microarray the and detection disease risk scale we global well Array, Life disease research Axiom Solutions, for then studies use as populations, high-throughput Science population across in a programs. launched in human research genomic as
during It's One Innovative being launches. Fast for Company the of Companies. recognition So impact external our driving our was highlight as great quarter other our of quarter named innovation customers. that team for another the strong of one is Most Magazine's product high-impact
pillar of Moving strategy. second our the to
year, ever. many unique they're us turning over in with more the customers' I've the connect to than and many Since years, are me partner with the trusted gives senior had as of executive meetings customers teams. We it our opportunity our to status beginning the
reinforce at they both navigate organization. challenges them face. across opportunities well our conversations as our to help the to and partnership happening that all is the as of This are These levels company
our Our as And finding every status see reinforce of our partner of theirs. better customers. customers to way day culture team trusted a always our part serves our with
with their innovation our lightly in we'll to productivity. trust the take them not partner And enable customers company. our do to have and We closely continue
example next-generation that Bayer precision a patients cancer sequencing-based this the sequencing a from our help benefit first diagnostic identify in of The clinical develop announced therapies. growing of collaboration In who Bayer's portfolio to companion we business. is next-generation quarter, may with will
The is Instrument our example second Analytical business.
We network the of are Astral in several support PFAS as research they contamination. North to and state-of-the-art Collaboratory This the their research. in Carolina help capacity with partnering they'll to instruments, first identify And state PFAS address solutions kind. is including implement Orbitrap the use of our its to
needs. finally, portfolio testing of to customers their qPCR-based our life Clinical expanded GMP our contaminants X status lab share comes And allowing trusted delivery the include look I'll in testing We for This significantly results partner bacteria our to biosafety business, in offering as solutions of services capabilities medicines Research of detection to unmet patients. our versus quicker of to traditional how and examples faster medicines. for for method, other enables
Syndicated CorEvitas Registry patients the pustular psoriasis launched evidence to need we to unmet rare And outcomes Clinical with generalized disease. for address an real-world this in related for
recall, CorEvitas patients. very year. well business last became you and for company a of our part and difference As customers The making our is performing
our are trusted these All examples of partner status. great of
engages every a enables and turn find way me during quarter. Now our better to empowers which of day. execution Business System, outstanding to PPI let PPI the colleagues our all
the in delivered quarter. first You can and cash it see profitability flow strong our that in we
of as efficiency our PPI the Looking team as the AI is productivity improve and to as to across to generative utilizing forward, part System customer the Business increase well experience company. actively continue
models Life couple and accelerate timelines software Solutions our data Science a in Instruments also the a how with share differentiated it's We're at development To enabling of and examples our applying combination leveraging amount disposal. Analytical large we're vast AI, language of us of to of businesses.
and seeing more effectively Business AI service teams our impact the is serve to ability our of the great we the One benefit capability continually our customers. we're to System. of of PPI another is example enhance strengthen how customer technical Generative
update on responsibility Let me give initiatives. corporate you now social our an
a As the our world help make the work by of customers. important we better company, a enabling mission-driven place to
our global We education health steward our and impact supporting the equity. positive a focusing communities, by also good being [indiscernible] a advancing and have on of planet
first program during I'm facility on the Human biology on with announced Research education professional and scientists professionals and South Medical for to provide we'll will in support The score center share end, sciences. life Index laboratory Corporate establish Campaign a a to row. the we Africa. pleased that perfect Foundation's development also in that Rights Equality a focused and To Council. achieved specialized eighth of a molecular Fisher Together, year the Thermo training and quarter, the collaboration African excellence for
me now update give Let on deployment. capital you an
capital a which to strategy, returning strategic our shareholders. continue of deployment execute to successfully M&A our combination We and disciplined capital is
of of ahead now acquisition, anniversary business. During is the exciting new diagnostics growth. of great chance and tracking patient the the quarter, performance recently really protein diagnostics products can Site positively myeloma. deal progress had reached headquarters impact The I we for strong Its the multiple X-year that the protein model business our to with given they're financial our care Binding the visit making, saw
later on look $X the Olink. mid-XXXX. by And process, increased working We dividend regulatory new year. the repurchased terms quarter, and close through our of to planned We're capital company in Turning our transaction acquisition the to during the return of this track to and billion welcoming is colleagues shares XX%. forward by of of to we
success. accomplished quarter, once the Companies. for what and As team on contributions record, their both has I'm team recognition List Most Magazine's our on again included of of a In our nice I been and reflect proud Fisher Thermo very track Fortune of to Admired grateful our
to our now me turn Let guidance.
be the Given expect of remarks. We you the billion, to of per be to raising share. $XX.XX year, the expect our revenue Stephen EPS we take to in will performance the range billion his through details are in range guidance. the in to and $XX.X the adjusted stronger $XX.XX start we $XX.X at operational of XXXX now
and takeaways first financial driven another our So proven our PPI quarter of delivered to key summarize results strategy quarter. System. strong from by growth We Business the
status. We success, continue trusted customer this to our and reinforces partner continually our enable
for position XXXX stakeholders future deliver an even create and differentiated performance strong brighter results we build in of Our us our our to as to company. for continue in QX value all
With Stephen the to our call Williamson. that, I'll now CFO, over hand Stephen?
